A. Hoos, R. Ibrahim, and A. Korman, Development of Ipilimumab: Contribution to a New Paradigm for Cancer Immunotherapy, Seminars in Oncology, vol.37, issue.5, pp.533-579, 2010.
DOI : 10.1053/j.seminoncol.2010.09.015

F. Hodi, O. Day, S. Mcdermott, and D. , Improved Survival with Ipilimumab in Patients with Metastatic Melanoma, New England Journal of Medicine, vol.363, issue.8, pp.711-734, 2010.
DOI : 10.1056/NEJMoa1003466
URL : http://www.nejm.org/doi/pdf/10.1056/NEJMoa1003466

C. Robert, L. Thomas, and I. Bondarenko, Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma, New England Journal of Medicine, vol.364, issue.26, pp.2517-2543, 2011.
DOI : 10.1056/NEJMoa1104621

M. Maio, J. Grob, and S. Aamdal, Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial, Journal of Clinical Oncology, vol.33, issue.10, pp.1191-96, 2015.
DOI : 10.1200/JCO.2014.56.6018
URL : http://europepmc.org/articles/pmc5795709

D. Schadendorf, F. Hodi, and C. Robert, Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma, Journal of Clinical Oncology, vol.33, issue.17, pp.1889-94, 2015.
DOI : 10.1200/JCO.2014.56.2736

J. Wolchok, B. Neyns, and G. Linette, Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study, The Lancet Oncology, vol.11, issue.2, pp.155-64, 2010.
DOI : 10.1016/S1470-2045(09)70334-1

A. Hoos, A. Eggermont, and S. Janetzki, Improved Endpoints for Cancer Immunotherapy Trials, JNCI Journal of the National Cancer Institute, vol.5, issue.9, pp.1388-97, 2010.
DOI : 10.1038/ncponc1183
URL : https://academic.oup.com/jnci/article-pdf/102/18/1388/17984850/djq310.pdf

J. Wolchok, A. Hoos, O. Day, and S. , Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria, 9 NCI Common Terminology Criteria for Adverse Events (CTCAE) v.3, pp.7412-7432, 2006.
DOI : 10.1158/1078-0432.CCR-09-1624

M. Postow, J. Chesney, and A. Pavlick, Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma, New England Journal of Medicine, vol.372, issue.21, pp.2006-2023, 2015.
DOI : 10.1056/NEJMoa1414428
URL : http://europepmc.org/articles/pmc5744258?pdf=render

C. Robert, G. Long, and B. Brady, Mutation, New England Journal of Medicine, vol.372, issue.4, pp.320-350, 2015.
DOI : 10.1056/NEJMoa1412082
URL : https://hal.archives-ouvertes.fr/hal-00699117

J. Weber, D. Angelo, S. Minor, and D. , Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, The Lancet Oncology, vol.16, issue.4, pp.375-84, 2015.
DOI : 10.1016/S1470-2045(15)70076-8

N. Aaronson, S. Ahmedzai, and B. Bergman, The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology, JNCI Journal of the National Cancer Institute, vol.85, issue.5, pp.365-76, 1993.
DOI : 10.1093/jnci/85.5.365

D. Osoba, G. Rodrigues, J. Myles, B. Zee, and J. Pater, Interpreting the significance of changes in health-related quality-of-life scores., Journal of Clinical Oncology, vol.16, issue.1, pp.139-183, 1998.
DOI : 10.1200/JCO.1998.16.1.139

A. Pickard, M. Neary, and D. Cella, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer, Health and Quality of Life Outcomes, vol.5, issue.1, p.70, 2007.
DOI : 10.1186/1477-7525-5-70
URL : https://hqlo.biomedcentral.com/track/pdf/10.1186/1477-7525-8-4?site=hqlo.biomedcentral.com

R. Brookmeyer and J. Crowley, A Confidence Interval for the Median Survival Time, Biometrics, vol.38, issue.1, pp.29-41, 1982.
DOI : 10.2307/2530286

J. Kalbfleisch and R. Prentice, The statistical analysis of failure time data, 2002.
DOI : 10.1002/9781118032985

S. Topalian, M. Sznol, and D. Mcdermott, Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab, Journal of Clinical Oncology, vol.32, issue.10, pp.1020-1050, 2014.
DOI : 10.1200/JCO.2013.53.0105
URL : http://europepmc.org/articles/pmc4811023?pdf=render

A. Ribas, O. Hamid, and A. Daud, Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma, JAMA, vol.315, issue.15, pp.1600-1609, 2016.
DOI : 10.1001/jama.2016.4059
URL : http://jama.jamanetwork.com/data/journals/jama/935217/joi160035.pdf

C. Robert, J. Schachter, and G. Long, Pembrolizumab versus Ipilimumab in Advanced Melanoma, New England Journal of Medicine, vol.372, issue.26, pp.2521-2553, 2015.
DOI : 10.1056/NEJMoa1503093

G. Long, J. Grob, and P. Nathan, Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, The Lancet Oncology, vol.17, issue.12, pp.1743-54, 2016.
DOI : 10.1016/S1470-2045(16)30578-2

P. Ascierto, G. Mcarthur, and B. Dreno, Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, The Lancet Oncology, vol.17, issue.9, pp.1248-60, 2016.
DOI : 10.1016/S1470-2045(16)30122-X

J. Larkin, V. Chiarion-sileni, and R. Gonzalez, Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma, New England Journal of Medicine, vol.373, issue.1, pp.23-34, 2015.
DOI : 10.1056/NEJMoa1504030
URL : http://www.zora.uzh.ch/id/eprint/113016/1/608_Larkin%20et%20al%20_NEJM%202015.pdf